These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 20832749)

  • 1. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.
    Wang JB; Erickson JW; Fuji R; Ramachandran S; Gao P; Dinavahi R; Wilson KF; Ambrosio AL; Dias SM; Dang CV; Cerione RA
    Cancer Cell; 2010 Sep; 18(3):207-19. PubMed ID: 20832749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho GTPases and their roles in cancer metabolism.
    Wilson KF; Erickson JW; Antonyak MA; Cerione RA
    Trends Mol Med; 2013 Feb; 19(2):74-82. PubMed ID: 23219172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.
    Lukey MJ; Greene KS; Erickson JW; Wilson KF; Cerione RA
    Nat Commun; 2016 Apr; 7():11321. PubMed ID: 27089238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutaminase: a hot spot for regulation of cancer cell metabolism?
    Erickson JW; Cerione RA
    Oncotarget; 2010 Dec; 1(8):734-40. PubMed ID: 21234284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies impacting cancer cell glutamine metabolism.
    Lukey MJ; Wilson KF; Cerione RA
    Future Med Chem; 2013 Sep; 5(14):1685-700. PubMed ID: 24047273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells.
    Stalnecker CA; Ulrich SM; Li Y; Ramachandran S; McBrayer MK; DeBerardinis RJ; Cerione RA; Erickson JW
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):394-9. PubMed ID: 25548170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.
    Jeay S; Pianetti S; Kagan HM; Sonenshein GE
    Mol Cell Biol; 2003 Apr; 23(7):2251-63. PubMed ID: 12640111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.
    Wang L; Yang L; Luo Y; Zheng Y
    J Biol Chem; 2003 Nov; 278(45):44617-25. PubMed ID: 12939257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
    Shutes A; Onesto C; Picard V; Leblond B; Schweighoffer F; Der CJ
    J Biol Chem; 2007 Dec; 282(49):35666-78. PubMed ID: 17932039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay.
    Blangy A; Bouquier N; Gauthier-Rouvière C; Schmidt S; Debant A; Leonetti JP; Fort P
    Biol Cell; 2006 Sep; 98(9):511-22. PubMed ID: 16686599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation.
    Saito S; Liu XF; Kamijo K; Raziuddin R; Tatsumoto T; Okamoto I; Chen X; Lee CC; Lorenzi MV; Ohara N; Miki T
    J Biol Chem; 2004 Feb; 279(8):7169-79. PubMed ID: 14645260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases.
    Berenjeno IM; Núñez F; Bustelo XR
    Oncogene; 2007 Jun; 26(29):4295-305. PubMed ID: 17213802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rho GTPases: promising cellular targets for novel anticancer drugs.
    Fritz G; Kaina B
    Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression.
    Bozza WP; Zhang Y; Hallett K; Rivera Rosado LA; Zhang B
    Oncotarget; 2015 Oct; 6(32):32723-36. PubMed ID: 26416248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomolecular Interaction Assays Identified Dual Inhibitors of Glutaminase and Glutamate Dehydrogenase That Disrupt Mitochondrial Function and Prevent Growth of Cancer Cells.
    Zhu M; Fang J; Zhang J; Zhang Z; Xie J; Yu Y; Ruan JJ; Chen Z; Hou W; Yang G; Su W; Ruan BH
    Anal Chem; 2017 Feb; 89(3):1689-1696. PubMed ID: 28208301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditions for activity of glutaminase in kidney mitochondria.
    Kovacević Z; McGivan JD; Chappell JB
    Biochem J; 1970 Jun; 118(2):265-74. PubMed ID: 5530189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Rho GTPases in breast cancer.
    Tang Y; Olufemi L; Wang MT; Nie D
    Front Biosci; 2008 Jan; 13():759-76. PubMed ID: 17981586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rho GTPase expression in tumourigenesis: evidence for a significant link.
    Gómez del Pulgar T; Benitah SA; Valerón PF; Espina C; Lacal JC
    Bioessays; 2005 Jun; 27(6):602-13. PubMed ID: 15892119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.
    Fidyk N; Wang JB; Cerione RA
    Biochemistry; 2006 Jun; 45(25):7750-62. PubMed ID: 16784226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.